U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Center for Drug Evaluation and Research | CDER
  5. Office of Neuroscience - Division of Psychiatry
  1. Center for Drug Evaluation and Research | CDER

Office of Neuroscience - Division of Psychiatry


The Office of New Drugs is undergoing a reorganization. This site will be updated in the near future.  Please check back often.  For more information, please visit: Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality. Until this page is updated, please use the current contact information presented on this page or contact druginfo@fda.hhs.gov if you have additional questions.

The Division of Psychiatry (DP) regulates and reviews Investigational New Drug (IND) applications and marketing applications for products for the treatment of psychiatric diseases and conditions, such as bipolar disorder, schizophrenia, schizoaffective disorder, major depressive disorder, attention deficit hyperactivity disorder, obsessive-compulsive disorder, panic attacks, posttraumatic stress disorder, generalized anxiety disorder, autism spectrum disorder, and insomnia.

  • Director: Tiffany R. Farchione, M.D. (Acting)
  • Deputy Director: TBD
  • Deputy Director for Safety: Marc Stone, M.D.
  • Safety Regulatory Project Manager: Ermias Zerislassie, Pharm.D.
  • Regulatory Operations Chief, Project Management Staff: Paul David, R.Ph. and Steve Hardeman, R.Ph.

Contact Us:

Mailing Address: 

10903 New Hampshire Avenue, Silver Spring, MD 20993
Building 22, Suite 4200
Phone: (301) 796-2260
Fax: (301) 796-9841




Back to Top